Although imatinib enhances CXCR4 expression in CML cells, and MSCs protect these CML cells from imatinib-induced apoptosis, MSCs further enhance the capacity of imatinib to induce CML cell cycle arrest in the G0/G1 phase. Here, CXCR4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.